Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1733.TW Stock Summary
Top 10 Correlated ETFs
1733.TW
In the News
1733.TW Financial details
Company Rating
Strong Buy
Market Cap
3.5B
Income
115.78M
Revenue
1.68B
Book val./share
17.97
Cash/share
4.44
Dividend
1.4
Dividend %
4.24%
Employees
641
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
22.87
Forward P/E
-
PEG
-6.31
P/S
2
P/B
1.85
P/C
7.66
P/FCF
37.22
Quick Ratio
1.86
Current Ratio
4.02
Debt / Equity
0.1
LT Debt / Equity
0.06
-
-
EPS (TTM)
1.16
EPS next Y
-
EPS next Q
-
EPS this Y
-36.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0.35%
Revenue last 5Y
-5.28%
Revenue Q/Q
-0.55%
EPS Q/Q
-60.53%
-
-
-
-
SMA20
9.38%
SMA50
6.06%
SMA100
29.63%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
0.09%
Gross Margin
31%
Oper. Margin
10%
Profit Margin
8%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
25.6-44.45
52W High
-22.73%
52W Low
+36%
RSI
50
Rel Volume
0.4
Avg Volume
1.15M
Volume
458.62K
Perf Week
-10.05%
Perf Month
4.29%
Perf Quarter
27.82%
Perf Half Y
26.87%
-
-
-
-
Beta
0.421
-
-
Volatility
0.62%, 1.42%
Prev Close
0.74%
Price
34
Change
-0.73%
1733.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 22.01 | 20.15 | 21.37 | 22.45 | 16.77 | |
Net income per share | 1.14 | 0.95 | 2.03 | 1.82 | 1.16 | |
Operating cash flow per share | 4.63 | 2.82 | 1.8 | 0.27 | 2.31 | |
Free cash flow per share | 4.06 | 2.33 | 1.54 | -0.14 | 2.06 | |
Cash per share | 8.04 | 8.27 | 6.33 | 3.98 | 4.44 | |
Book value per share | 16.78 | 16.53 | 17.57 | 18.18 | 17.97 | |
Tangible book value per share | 15.22 | 15.24 | 16.52 | 17.5 | 17.98 | |
Share holders equity per share | 16.78 | 16.53 | 17.57 | 18.18 | 17.97 | |
Interest debt per share | 6.78 | 5.85 | 3.57 | 2.49 | 1.85 | |
Market cap | 2.83B | 2.36B | 2.59B | 2.55B | 4.03B | |
Enterprise value | 2.85B | 2.14B | 2.38B | 2.47B | 3.83B | |
P/E ratio | 24.87 | 24.89 | 12.82 | 14.05 | 34.79 | |
Price to sales ratio | 1.29 | 1.18 | 1.22 | 1.14 | 2.4 | |
POCF ratio | 6.12 | 8.41 | 14.42 | 95.95 | 17.48 | |
PFCF ratio | 6.98 | 10.16 | 16.87 | -187.99 | 19.61 | |
P/B Ratio | 1.69 | 1.43 | 1.48 | 1.41 | 2.24 | |
PTB ratio | 1.69 | 1.43 | 1.48 | 1.41 | 2.24 | |
EV to sales | 1.29 | 1.07 | 1.12 | 1.1 | 2.28 | |
Enterprise value over EBITDA | 9.84 | 9.5 | 8.22 | 8.25 | 17.17 | |
EV to operating cash flow | 6.15 | 7.64 | 13.24 | 92.65 | 16.61 | |
EV to free cash flow | 7.01 | 9.23 | 15.49 | -181.53 | 18.63 | |
Earnings yield | 0.04 | 0.04 | 0.08 | 0.07 | 0.03 | |
Free cash flow yield | 0.14 | 0.1 | 0.06 | -0.01 | 0.05 | |
Debt to equity | 0.4 | 0.35 | 0.2 | 0.13 | 0.1 | |
Debt to assets | 0.24 | 0.22 | 0.13 | 0.1 | 0.08 | |
Net debt to EBITDA | 0.05 | -0.95 | -0.73 | -0.29 | -0.9 | |
Current ratio | 2.86 | 1.91 | 2.24 | 2.9 | 3.93 | |
Interest coverage | 17.96 | 11.73 | 15.48 | 37.97 | 32.3 | |
Income quality | 2.84 | 2.54 | 0.97 | 0.13 | 1.63 | |
Dividend Yield | 0.03 | 0.05 | 0.04 | 0.05 | 0.03 | |
Payout ratio | 0.74 | 1.16 | 0.54 | 0.71 | 1.21 | |
Sales general and administrative to revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.07 | |
Research and developement to revenue | 0.07 | 0.08 | 0.07 | 0.07 | 0.1 | |
Intangibles to total assets | 0.06 | 0.05 | 0.04 | 0.03 | 0.02 | |
Capex to operating cash flow | -0.12 | -0.17 | -0.15 | -1.51 | -0.11 | |
Capex to revenue | -0.03 | -0.02 | -0.01 | -0.02 | -0.01 | |
Capex to depreciation | -0.49 | -0.46 | -0.27 | -0.43 | -0.33 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 20.74 | 18.82 | 28.32 | 27.28 | 21.64 | |
ROIC | 0.05 | 0.04 | 0.1 | 0.09 | 0.06 | |
Return on tangible assets | 0.04 | 0.04 | 0.08 | 0.07 | 0.05 | |
Graham Net | 2.58 | 3.28 | 3.96 | 4.43 | 5.39 | |
Working capital | 1.16B | 801.05M | 973.97M | 1.08B | 1.12B | |
Tangible asset value | 1.52B | 1.52B | 1.65B | 1.75B | 1.75B | |
Net current asset value | 640.37M | 679.2M | 842.94M | 957.67M | 1.01B | |
Invested capital | 0.4 | 0.35 | 0.2 | 0.13 | 0.1 | |
Average receivables | 480.67M | 394.36M | 415.53M | 492.63M | 395.5M | |
Average payables | 198.02M | 202.53M | 236.03M | 255.81M | 177.62M | |
Average inventory | 578.39M | 509.42M | 566.56M | 683.92M | 743.48M | |
Days sales outstanding | 74.04 | 62.37 | 83.62 | 80.82 | 64.03 | |
Days payables outstanding | 49.51 | 43.93 | 66.71 | 49.57 | 41.04 | |
Days of inventory on hand | 116.72 | 118.57 | 147.06 | 161.83 | 238.27 | |
Receivables turnover | 4.93 | 5.85 | 4.36 | 4.52 | 5.7 | |
Payables turnover | 7.37 | 8.31 | 5.47 | 7.36 | 8.89 | |
Inventory turnover | 3.13 | 3.08 | 2.48 | 2.26 | 1.53 | |
ROE | 0.07 | 0.06 | 0.12 | 0.1 | 0.06 | |
Capex per share | -0.57 | -0.49 | -0.26 | -0.4 | -0.25 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.09 | 4.37 | 4.17 | 4.13 | 4.1 | |
Net income per share | 0.43 | 0.36 | 0.27 | 0.38 | 0.15 | |
Operating cash flow per share | -0.02 | -0.39 | 1.33 | 0.29 | 1.08 | |
Free cash flow per share | -0.07 | -0.46 | 1.24 | 0.25 | 1.03 | |
Cash per share | 3.98 | 3.43 | 4.26 | 3.13 | 4.44 | |
Book value per share | 18.18 | 17.14 | 17.42 | 17.81 | 17.97 | |
Tangible book value per share | 17.5 | 16.47 | 16.75 | 17.16 | 17.98 | |
Share holders equity per share | 18.18 | 17.14 | 17.42 | 17.81 | 17.97 | |
Interest debt per share | 2.46 | 2.1 | 1.66 | 1.56 | 1.82 | |
Market cap | 2.55B | 2.58B | 2.84B | 2.68B | 4.03B | |
Enterprise value | 2.47B | 2.51B | 2.64B | 2.59B | 3.83B | |
P/E ratio | 14.8 | 18.04 | 26.31 | 17.72 | 66.39 | |
Price to sales ratio | 5.02 | 5.91 | 6.81 | 6.51 | 9.82 | |
POCF ratio | -1.57K | -65.66 | 21.43 | 91.28 | 37.45 | |
PFCF ratio | -342.74 | -55.67 | 22.92 | 107.06 | 39.25 | |
P/B Ratio | 1.41 | 1.51 | 1.63 | 1.51 | 2.24 | |
PTB ratio | 1.41 | 1.51 | 1.63 | 1.51 | 2.24 | |
EV to sales | 4.85 | 5.75 | 6.33 | 6.27 | 9.33 | |
Enterprise value over EBITDA | 36.36 | 36.99 | 49.35 | 37.9 | 122.03 | |
EV to operating cash flow | -1.51K | -63.93 | 19.92 | 88 | 35.58 | |
EV to free cash flow | -330.95 | -54.2 | 21.31 | 103.21 | 37.29 | |
Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Free cash flow yield | 0 | -0.02 | 0.04 | 0.01 | 0.03 | |
Debt to equity | 0.13 | 0.12 | 0.09 | 0.09 | 0.1 | |
Debt to assets | 0.1 | 0.09 | 0.07 | 0.07 | 0.08 | |
Net debt to EBITDA | -1.29 | -1 | -3.74 | -1.41 | -6.42 | |
Current ratio | 2.9 | 2.7 | 2.94 | 4.02 | 3.93 | |
Interest coverage | 28.8 | 28.93 | 38.42 | 56.21 | 40.56 | |
Income quality | -0.04 | -0.84 | 3.96 | 0.61 | 8.71 | |
Dividend Yield | 0 | 0 | 0 | 0.05 | 0 | |
Payout ratio | 0 | 0 | 0 | 3.7 | 0 | |
Sales general and administrative to revenue | 0.06 | 0.07 | 0.07 | 0.08 | 0.06 | |
Research and developement to revenue | 0.09 | 0.09 | 0.09 | 0.1 | 0.11 | |
Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
Capex to operating cash flow | 3.57 | 0.18 | -0.07 | -0.15 | -0.05 | |
Capex to revenue | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | |
Capex to depreciation | -0.25 | -0.36 | -0.45 | -0.23 | -0.27 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 13.29 | 11.74 | 10.29 | 12.32 | 7.83 | |
ROIC | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | |
Return on tangible assets | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | |
Graham Net | 4.43 | 3.5 | 4.17 | 4.74 | 5.39 | |
Working capital | 1.08B | 993.49M | 1.03B | 1.08B | 1.12B | |
Tangible asset value | 1.75B | 1.65B | 1.67B | 1.72B | 1.75B | |
Net current asset value | 957.67M | 871.12M | 908.15M | 960.17M | 1.01B | |
Invested capital | 0.13 | 0.12 | 0.09 | 0.09 | 0.1 | |
Average receivables | 499.25M | 464.86M | 387.87M | 347.54M | 323.15M | |
Average payables | 248.08M | 204.99M | 154.68M | 117.93M | 119.4M | |
Average inventory | 715.99M | 759.87M | 775.15M | 759.31M | 748.26M | |
Days sales outstanding | 87.92 | 89.24 | 73.96 | 76.84 | 64.52 | |
Days payables outstanding | 58.1 | 54.63 | 38.49 | 35.98 | 42.36 | |
Days of inventory on hand | 189.68 | 232.35 | 235.44 | 244.88 | 245.93 | |
Receivables turnover | 1.02 | 1.01 | 1.22 | 1.17 | 1.39 | |
Payables turnover | 1.55 | 1.65 | 2.34 | 2.5 | 2.12 | |
Inventory turnover | 0.47 | 0.39 | 0.38 | 0.37 | 0.37 | |
ROE | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Capex per share | -0.06 | -0.07 | -0.09 | -0.04 | -0.05 |
1733.TW Frequently Asked Questions
What is Apex Biotechnology Corp. stock symbol ?
Apex Biotechnology Corp. is a TW stock and trading under the symbol 1733.TW
What is Apex Biotechnology Corp. stock quote today ?
Apex Biotechnology Corp. stock price is $34 today.
Is Apex Biotechnology Corp. stock public?
Yes, Apex Biotechnology Corp. is a publicly traded company.